Elamipretide / Stegazo — the FDA approval for Barth syndrome and what it signals

Barth syndrome was first described by the Dutch pediatrician Peter Barth in 1983. It is caused by mutations in the TAZ gene, which encodes an enzyme called tafazzin. Tafazzin is responsible for cardiolipin remodeling — a specific biochemical process in which the fatty acid side chains of newly synthesized cardiolipin are exchanged for a final mature composition that optimizes the lipid's structural function. Cardiolipin is the defining lipid of the inner mitochondrial membrane. It's found almost nowhere else in the cell. When it is properly composed and properly embedded in the membrane, it stabilizes the cristae folds that the electron transport chain depends on, facilitates the assembly of respiratory supercomplexes, and supports the membrane potential that drives ATP synthesis. When tafazzin fails — as it does in every cell of every person with Barth syndrome — immature cardiolipin accumulates, mature cardiolipin is depleted, and the mitochondrial infrastructure of the inner membrane is structurally compromised from birth.

The clinical consequences follow from this structural failure with a consistency that is unusual even in genetic disease. Virtually all affected individuals develop dilated cardiomyopathy — the heart enlarges as its muscle cells struggle to sustain adequate contractile function with deficient mitochondrial energy production. Skeletal myopathy affects the striated muscles of the limbs and trunk, producing the weakness and exercise intolerance that limit daily activity. Neutropenia — abnormally low neutrophil counts — increases infection risk and was historically the cause of septic crises that could be rapidly fatal. Growth retardation reflects the systemic energetic deficit that begins in utero. All of this in young males — the condition is X-linked recessive, which means females typically carry one functional copy of the gene and are not clinically affected, while males who inherit the mutated copy have the full syndrome.

The syndrome is rare. Estimates suggest roughly 1 in 300,000 to 400,000 live births, though underdiagnosis has historically obscured the true number. For the families living with it, the rarity translates into a specific experience: limited disease awareness among general practitioners, sparse clinical infrastructure, and for decades no approved pharmacological treatment designed for the condition. Management was supportive — heart failure medications borrowed from adult cardiology, antibiotic prophylaxis during neutropenic periods, nutritional support. The underlying cardiolipin biology was understood, but intervening in it directly was not something the available pharmacopeia could do.

Elamipretide is the tetrapeptide developed by Hazel Szeto and Peter Schiller with the specific property of binding cardiolipin in the inner mitochondrial membrane. The design logic, described in detail elsewhere in this library, is that the peptide's alternating aromatic-cationic structure gives it selective affinity for the strongly negative inner mitochondrial membrane, and once there, the aromatic amino acid dimethyltyrosine interacts directly with cardiolipin's head groups. The effect is structural stabilization: preserved cristae curvature, maintained organization of the electron transport chain supercomplexes, reduced oxidative damage at the membrane level, and improved mitochondrial function downstream.

The early clinical programs for elamipretide — conducted by Stealth BioTherapeutics under the brand name MTP-131 — targeted heart failure and primary mitochondrial myopathy. These trials, in heterogeneous adult populations, produced mixed results. The EMBRACE program in heart failure with preserved ejection fraction did not demonstrate the clear efficacy needed for broad approval. The MMPOWER program in primary mitochondrial myopathy had a more nuanced outcome, with some measures of exercise tolerance showing positive trends but the primary endpoints not achieving significance in the full population. These results were frustrating for a field that had found the mechanism compelling in preclinical work.

The redirection toward Barth syndrome was not a retreat. It was the most logical application of the mechanism — a disease defined by the specific biochemical failure that elamipretide was designed to address. In Barth syndrome, cardiolipin remodeling failure is not a contributing factor in a complex disease; it is the disease. Every cell of every affected individual has structurally compromised inner mitochondrial membranes because of this specific genetic defect. If elamipretide's cardiolipin-stabilizing mechanism was real and clinically meaningful, Barth syndrome patients were the population most likely to show it.

The TAZPOWER trial was designed to test this directly. It was a double-blind, randomized, placebo-controlled crossover study — patients received elamipretide for twelve weeks and placebo for twelve weeks, or vice versa, with a washout period between. The primary outcomes included the six-minute walk test, a measure of functional exercise capacity that is meaningful in a population with cardiomyopathy and skeletal myopathy, and a patient-reported fatigue score. Secondary measures included echocardiographic parameters of cardiac function and additional functional assessments.

The results were positive. Patients on elamipretide walked farther in the six-minute walk test and reported less fatigue compared to their own placebo phase. Cardiac function measures improved in the treatment phase. The crossover design has inherent advantages in a small rare-disease population: each patient serves as their own control, which increases statistical power and reduces the confounding that plagues between-group comparisons in heterogeneous diseases. An open-label extension study followed participants after the blinded trial and showed that functional improvements were sustained and in some cases continued to evolve with longer treatment duration.

The FDA granted accelerated approval for elamipretide — marketed as Stegazo — for the treatment of Barth syndrome in 2023. This was the first approval of any treatment specifically indicated for Barth syndrome. It was also the first FDA approval of a cardiolipin-targeted therapy — a regulatory first that validates a therapeutic target that had previously existed only in research publications.

Accelerated approval requires clarification. Under the accelerated approval pathway, the FDA can approve a drug based on evidence of effect on a surrogate or intermediate endpoint that is reasonably likely to predict clinical benefit, when the drug treats a serious condition with unmet need. Post-marketing confirmatory trials are required; if those trials don't confirm clinical benefit, the approval can be withdrawn. Stegazo's approval is conditional in this technical sense — it reflects the FDA's judgment that the available evidence is sufficient to justify approval in a population with no prior options, while requiring ongoing confirmatory work. This is a meaningful and legitimate approval. It is not a full traditional approval, and the distinction is worth making accurately.

The price and access dimensions of rare disease approvals are a separate conversation that the Stegazo approval doesn't escape. Drugs developed for ultra-rare conditions, where the patient population is small and the development costs are high, tend to carry prices that generate significant debate about fairness, sustainability, and who ultimately bears the cost. Stegazo entered this territory. These are real questions without clean answers — the pricing reflects the economics of rare disease drug development in the current regulatory and commercial environment, and the same drug that is inaccessible at its list price for many patients represents a genuine advance for Barth syndrome families who can access it through payer coverage or patient assistance programs. Both things are true. Acknowledging the tension is more honest than resolving it artificially.

What the approval signals mechanistically is the most important thing for the broader context of mitochondrial medicine. The FDA has now formally agreed, through the standard regulatory evidence process, that a peptide designed to bind cardiolipin in the inner mitochondrial membrane produces measurable clinical benefit in a disease defined by cardiolipin remodeling failure. This is not a trivial finding. The entire mechanism that Szeto built SS-31 around — the idea that mitochondrial membrane geometry is a therapeutic target, that cardiolipin is a druggable lipid, that protecting this specific structural element can change functional outcomes in disease — has now received its first regulatory endorsement.

The implication for other mitochondrial diseases is not that Stegazo will work for all of them. The Barth syndrome results are specific to a disease where cardiolipin dysfunction is the genetic primary driver. In conditions where mitochondrial dysfunction is one contributor among many, the effect size may be smaller and the benefit harder to demonstrate cleanly. The heart failure experience suggests caution about overgeneralizing from the specific to the heterogeneous. What the Barth syndrome approval justifies is continuing to develop elamipretide for other diseases where cardiolipin damage is mechanistically primary — diseases where you can say, with genetic or biochemical confidence, that the inner membrane is the bottleneck and cardiolipin is the lipid that needs protection.

Leber's hereditary optic neuropathy, Friedreich's ataxia, and primary mitochondrial myopathies are the ongoing programs where this question is being tested. Each involves mitochondrial dysfunction with inner membrane involvement; the degree to which cardiolipin damage is primary versus secondary differs across conditions. The clinical trials will take years to complete. The mechanistic hypothesis they're testing has now been validated at least once in a controlled regulatory setting.

For a three-year-old boy and his family sitting across from a geneticist with a new diagnosis, this matters in the most immediate possible way. For researchers building the next generation of mitochondrial therapies, it matters as evidence that the inner membrane is a real target and that the approach of designing molecules that find it specifically can work. For the field broadly, it represents the opening of a mechanistic door that had been theoretically interesting for decades and is now operationally real — a first approval, a validated target, and a set of open questions worth spending the next decade answering.